UPDATE 2-Eli Lilly cuts 2019 forecast on trial failure, Loxo deal

Eli Lilly and Co cut its 2019 forecast for profit and revenue on Wednesday, citing the recent trial failure of its conditionally approved cancer drug Lartruvo and costs related to its pending acquisition of Loxo Oncology.